Physician survey in India with 164 ivermectin prophylaxis, 129 HCQ prophylaxis, and 81 control patients, showing significantly lower COVID-19 cases with treatment. Details of the treatment and control groups and the definition of cases are not provided, and the results are subject to survey bias. Authors also report on community prophylaxis but present only combined ivermectin/HCQ results.
This study is excluded in the after exclusion results of meta-analysis:
minimal details provided; unadjusted results with no group details; results may be significantly affected by survey bias.
Study covers
HCQ and ivermectin.
OutcomeImprovementEffect · pTreatmentControl
risk of case
79.8% lower · RR 0.20 · p < 0.001***
79.8% lowerRR 0.20p < 0.001***
12 of 164 (7.3%)
29 of 81 (35.8%)
treatment 12 of 164 (7.3%), control 29 of 81 (35.8%)physician surveyNNT 3.5odds ratio converted to relative risk
risk of case
48.6% lower · RR 0.51 · p = 0.03*
48.6% lowerRR 0.51p = 0.03*
11 of 109 (10.1%)
39 of 200 (19.5%)
treatment 11 of 109 (10.1%), control 39 of 200 (19.5%)combined ivermectin or HCQ in communityNNT 11odds ratio converted to relative risk
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates. * p < 0.05 *** p < 0.001
Samajdar et al., 17 Nov 2021, retrospective, India, peer-reviewed, 9 authors, study period 1 September, 2020 - 31 December, 2020, dosage not specified.
